Lack of mda-6/WAF1/CIP1 -mediated inhibition of cyclin-dependent kinases in interferon-α resistant murine B16 melanoma cells

Cancer Letters

Volumn 119, Issue 2, 1997, Pages 237-240

  Arany, Istvan ^a   Fleischmann, Christina M ^a   Tyring, Stephen K ^a   Fleischmann Jr , W Robert ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Growth inhibition; Interferons; Melanoma; Resistance

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GAMMA INTERFERON; PROTEIN P53;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME REGULATION; GROWTH REGULATION; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG RESISTANCE, NEOPLASM; ENZYME REPRESSION; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0030714555     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00288-7     Document Type: Article

References (14)

1. O. Kloke, N. Niederle, Development and mechanisms of interferon resistance, Cancer Treat. Rev. 17 (1990) 81-88.
2. G. Della Porta, Cellular and molecular biology of melanoma, Semin. Surg. Oncol. 8 (1992) 353-357.
3. N.A. Saunders, A.M. Jetten, Control of growth regulatory and differentiation-specific genes in human epidermal keratinocytes by Interferon γ. Antagonism by retinoic acid and transforming growth factor β1, J. Biol. Chem. 269 (1994) 2016-2022.
4. M.M. Brysk, I. Arany, H. Brysk, S.-H. Chen, K.H. Calhoun, S.K. Tyring, Epithelial cell responsiveness to interferon gamma: epidermis vs. buccal mucosa, Mol. Cell. Differ. 3 (1995) 213-223.
5. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, R.H. Blum, Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684, J. Clin. Oncol. 14 (1996) 7-17.
6. W.R.J. Fleischmann, C.M. Fleischmann, Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice, Cancer Immunol. Immunother. 39 (1994) 148-154.
7. S. Koren, W.R.J. Fleischmann, Quantitation of in vivo potentiation resulting from combined interferon therapy: antitumor effect against B-16 melanoma in mice, J. Interferon Res. 6 (1986) 473-482.
8. W.R.J. Fleischmann, Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence, Cancer Res. 42 (1982) 869-875.
9. W. Lasek, A. Wankowicz, K. Kuc, W. Feleszko, J. Golab, A. Giermasz, W. Wiktor-Jedrzejczak, M. Jakobisiak, Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice, Cancer Immunol. Immunother. 40 (1995) 315-321.
10. I. Arany, C.M. Fleischmann, S.K. Tyring, W.R. Fleischmann Jr., Interferon regulates the expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells, Biochem. Biophys. Res. Commun. 233 (1997) 678-680.
11. H. Jiang, J. Lin, Z.Z. Su, M. Herlyn, R.S. Kerbel, B.E. Weissman, D.R. Welch, P.B. Fisher, The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells, Oncogene 10 (1995) 1855-1864.
12. S. Koren, E.B. Whorton Jr., W.R. Fleischmann Jr., Circadian dependence of interferon antitumor activity in mice, Int. J. Cancer 85 (1993) 1927-1931.
13. I. Arany, P. Rady, S.K. Tyring, Interferon treatment enhances the expression of underphosphorylated (biologically active) retinoblastoma protein in human papillomavirus infected cells through the inhibitory TGFβ1/IFN/β cytokine pathway, Antivirus Res. 23 (1994) 131-141.
14. C.J. Marshall, Tumor suppressor genes, Cell 64 (1991) 313-326.